All In Biotech

Drug Trial Radar · NCT05320393

Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines

Phase II Multi-Ctr, Prospective, Randomized, Double Blind, Active-Controlled Single Treatment Increasing Dose Trial to Study Safety & Duration of Effect of 40U of PrabotulinumtoxinA-xvfs in Adult Subjects for Treatment of Glabellar Lines

Last checked: Nov 20, 2026Latest source record: Sep 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

154

Actual

Start

Mar 30, 2022

Primary completion

May 22, 2023

Study completion May 22, 2023

Sponsor

Lead sponsor
Evolus, Inc.Industry
Sponsor type
Industry
Collaborators
ethica Clinical Research Inc.
First posted
Apr 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown lines, which are the vertical lines that develop between the eyebrows) in adult participants. It will also determine if the duration of effect of 40 Units of Jeuveau® is greater than that of 20 Units of Jeuveau® and 20 Units of Botox® Cosmetic.

Conditions

  • Glabellar Frown Lines

Interventions

  • PrabotulinumtoxinA-XvfsDrug

    One treatment of 40 units

  • OnabotulinumtoxinADrug

    One treatment of 20 units

  • PrabotulinumtoxinA-XvfsDrug

    One treatment of 20 units

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Effect Described by Kaplan-Meier AnalysisTime frame: Duration of effect for each subject will be based on number of days from baseline to the day that Glabellar Line Scale severity (Investigator Assessment) returns to baseline value, assessed every 30 days up to 365 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aesthetic Eyelid Plastic Surgery

    Boca Raton, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.